Human Transforming Growth Factor β3 (hTGF-β3) #8425
We recommend the following alternatives
#
Product Name
Inquiry Info. # 8425
Please see our recommended alternatives.
Product Information
Product Usage Information
Reconstitution:
With carrier: Add sterile 20 mM Citrate, pH 3.0 to a final hTGF-β3 concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.
Carrier free: Add sterile 20 mM Citrate, pH 3.0, or 20 mM Citrate, pH 3.0 containing protein to minimize absorption of hTGF-β3 to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock hTGF-β3 should be greater than 50 μg/ml.
Formulation
Storage
Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
Product Description
| MW (kDa) | 12 |
| Purity | >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-β3. Less than 5% migrates as monomer hTGF-β3 under non-reduced (-) conditions. All lots are greater than 98% pure. |
| Endotoxin | Less than 0.01 ng endotoxin/1 μg hTGF-β3. |
| Activity | The bioactivity of recombinant hTGF-β3 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 0.02-0.1 ng/ml. |
| Molecular Formula | Recombinant hTGF-β3 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,722. DTT-reduced protein migrates as a 12 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 22 kDa protein. The expected amino-terminal ALDTN of recombinant hTGF-β3 was verified by amino acid sequencing. |
Source / Purification
Background
- Siegel, P.M. and Massagué, J. (2003) Nat Rev Cancer 3, 807-21.
- Bierie, B. and Moses, H.L. (2006) Nat Rev Cancer 6, 506-20.
- Damstrup, L. et al. (1993) Br J Cancer 67, 1015-21.
- Constam, D.B. et al. (1992) J Immunol 148, 1404-10.
- Moustakas, A. and Heldin, C.H. (2009) Development 136, 3699-714.
- Dünker, N. and Krieglstein, K. (2000) Eur J Biochem 267, 6982-8.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.